Home › Drug Use and Addiction › NCT06859710
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RecruitingPhase 1Healthy volunteers welcome
Interactions Between Delta-9-THC and CBD: A Controlled Human Drug-administration Study Probing a Harm Reduction Strategy
Who can join
Ages 21 to 55 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Male or non-pregnant and non-lactating females aged 21-55 years * Report cannabis use 1-7 days per week over the month prior to screening * Not currently seeking treatment for their cannabis use * History of inhaled cannabis use * Have a Body Mass Index from 18.5 - 34 kg/m2 * Able to perform all study procedures * Must be using a contraceptive (hormonal or barrier methods) Exclusion Criteria: * Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD * Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent. * Report using other illicit drugs in the prior 4 weeks * Current pain * Pregnancy * Currently enrolled in another research protocol * Not using a contraceptive method (hormonal or barrier methods) * Insensitivity to the cold water stimulus of the Cold Pressor Test * Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history. * Not able to speak and read English
About the study
The purpose of this research is to assess the impact of CBD on the effects of THC.
What is being tested
- Placebo (drug)
- THC (drug)
- CBD 20 mg (drug)
- CBD 40 mg (drug)
- CBD 80 mg (drug)
Sponsor: University of California, Los Angeles · Participants: 30 · Started: Nov 5, 2025
Contact the study team
- Ziva Cooper, PhD · Phone: 310-206-9942
- Vincent Acebo · Phone: 310-983-3417
Official record on ClinicalTrials.gov — NCT06859710
Locations in the U.S.
| California | UCLA Center for Cannabis and Cannabinoids, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.